|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.46 USD | -0.57% |
|
+6.35% | -29.15% |
| 12-12 | Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating | MT |
| 12-12 | Rate Cuts Can't Buy Confidence |  |
| Capitalization | 11.51B 9.81B 9.16B 8.62B 15.87B 1,043B 17.33B 107B 41.47B 491B 43.19B 42.28B 1,793B | P/E ratio 2025 * |
-3.61x | P/E ratio 2026 * | -4.16x |
|---|---|---|---|---|---|
| Enterprise value | 5.99B 5.1B 4.76B 4.48B 8.25B 542B 9.02B 55.62B 21.57B 256B 22.47B 21.99B 933B | EV / Sales 2025 * |
3.14x | EV / Sales 2026 * | 4.17x |
| Free-Float |
90.48% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | -0.57% | ||
| 1 week | +6.35% | ||
| Current month | +13.39% | ||
| 1 month | +18.93% | ||
| 3 months | +25.31% | ||
| 6 months | +10.46% | ||
| Current year | -29.15% |
| 1 week | 26.9 |  | 30.44 |
| 1 month | 22.28 | | 30.44 |
| Current year | 22.28 | | 48.92 |
| 1 year | 22.28 | | 48.92 |
| 3 years | 22.28 | | 212.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 52 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 48 | 05/09/2022 |
Stephen Hoge
PSD | President | 49 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 31/05/2018 |
Noubar Afeyan
CHM | Chairman | 62 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 52 | 28/02/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.57% | +6.35% | -29.57% | -85.90% | 11.51B | |
| -0.74% | +3.19% | +1.37% | -1.16% | 76.06B | |
| -2.51% | -3.34% | -35.22% | -39.66% | 58.92B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | |
| +0.51% | -4.71% | +27.49% | +221.07% | 52.48B | |
| +0.93% | -3.97% | +16.04% | -39.77% | 25.54B | |
| -4.05% | -4.50% | +125.52% | +151.93% | 18.76B | |
| -0.72% | -6.94% | +39.18% | +15.41% | 18.73B | |
| -4.52% | -5.15% | +36.59% | +998.98% | 15.67B | |
| +1.46% | +2.05% | +173.37% | +686.91% | 14.48B | |
| Average | -0.88% | -1.33% | +42.40% | +197.70% | 34.52B | |
| Weighted average by Cap. | -0.66% | -0.49% | +27.18% | +114.68% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.91B 1.63B 1.52B 1.43B 2.63B 173B 2.87B 17.73B 6.88B 81.48B 7.16B 7.01B 297B | 1.96B 1.67B 1.56B 1.47B 2.7B 177B 2.95B 18.18B 7.05B 83.57B 7.34B 7.19B 305B |
| Net income | -3.14B -2.67B -2.5B -2.35B -4.33B -284B -4.73B -29.15B -11.31B -134B -11.78B -11.53B -489B | -2.8B -2.38B -2.23B -2.09B -3.86B -253B -4.21B -25.98B -10.08B -119B -10.5B -10.27B -436B |
| Net Debt | -5.52B -4.71B -4.4B -4.14B -7.61B -500B -8.32B -51.3B -19.9B -236B -20.72B -20.29B -860B | -3.35B -2.85B -2.66B -2.51B -4.62B -303B -5.04B -31.1B -12.06B -143B -12.56B -12.3B -522B |
More financial data
* Estimated data
Employees
5,800
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 29.46 $ | -0.57% | 12,305,889 |
| 11/12/25 | 29.63 $ | +2.07% | 8,179,780 |
| 10/12/25 | 29.03 $ | +2.80% | 7,685,972 |
| 09/12/25 | 28.24 $ | +0.97% | 11,701,381 |
| 08/12/25 | 27.97 $ | +0.97% | 10,972,985 |
Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
29.46USD
Average target price
35.37USD
Spread / Average Target
+20.06%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition